Fate’s management team has the passion and experience to explore new biology, develop innovative therapeutics, create formidable intellectual property, launch new business models and foster high-value strategic collaborations.
Mr. Wolchko is the President & Chief Executive Officer at Fate Therapeutics and is responsible for the company’s finance, administration and operations. Mr. Wolchko began his career as an investment banker with Morgan Stanley & Co., where he served for six years in the firm’s New York City and Menlo Park, California offices. As a member of Morgan Stanley’s Investment Banking Health Care Group, he assisted emerging growth companies in the health care technology sector complete capital-raising and M&A transactions. Prior to joining Fate Therapeutics, Mr. Wolchko served as the Chief Financial Officer of Bocada, Inc., where he oversaw all corporate service-related operations, and previously led Corporate Development at drugstore.com, where he was responsible for sourcing, evaluating and executing financial and business development opportunities. Mr. Wolchko holds an M.S. in biochemical engineering from the University of Virginia, and a B.S. in biomedical engineering from the University of Vermont.
Dr. Shoemaker is the Chief Scientific Officer at Fate Therapeutics and is overseeing the company’s discovery and preclinical development efforts. Dr. Shoemaker was previously Chief Scientific Officer of ICxBiosystems, where he led discovery and development of molecular tools to enrich and analyze rare cell populations with applications as advanced detection technologies for use in biodefense, cancer and prenatal diagnostics. Previously, Dr. Shoemaker was Chief Scientific Officer of GHC Technologies and led the research and development of rapid ultrasensitive detection assays for biodefense and clinical point-of-care diagnostics. From 1998 to 2003, Dr. Shoemaker held various positions of increasing responsibilities at Merck Research Laboratories, including Director of Target Discovery, Senior Director at Rosetta Inpharmatics and Research Fellow in the Department of Molecular Neurosciences, where his main focus was on target identification and biomarker discovery. Dr. Shoemaker’s research at Merck resulted in multiple publications in top scientific journals, including Nature, Science and Nature Biotechnology. Dr. Shoemaker received his Ph.D. in biochemistry from Stanford University and his B.S. in biochemistry from University of California, Santa Barbara.
Dr. Storgard is the Chief Medical Officer at Fate Therapeutics and is leading the company’s clinical development efforts. Dr. Storgard has more than 20 years of clinical research and pharmaceutical experience spanning from pre-clinical to Phase IV development. Previously, Dr. Storgard was the Vice President, Clinical Research and Development at Ardea Biosciences, a member of the AstraZeneca group, where he led the global clinical development of ZURAMPIC® to successful U.S. and European regulatory approvals. Before joining Ardea, he held senior positions in drug development and medical affairs at Prometheus Laboratories, Biogen Idec, and Amgen, where he focused on biologic and small molecule development programs within the inflammation and oncology teams. Dr. Storgard holds his M.D. from the University of Saskatchewan. He completed a fellowship in Rheumatology at Scripps Clinic and Research Center, and served as Senior Associate Consultant, Division of Rheumatology, and Assistant Professor and Member of the Molecular Medicine Program at the Mayo School of Medicine, Mayo Clinic in Minnesota.
Cindy Tahl is General Counsel at Fate Therapeutics and is serving as a key advisor in day to day operations, providing legal advice and counsel for all functions of the business and overseeing company compliance. Ms. Tahl also directs the development and expansion of the Company’s IP portfolio. Prior to joining Fate, Ms. Tahl was a technology transactions attorney at Wilson Sonsini Goodrich & Rosati, P.C., and practiced intellectual property law in the New York office of Kenyon & Kenyon, LLP. Ms. Tahl has worked extensively with biotechnology companies at all stages of growth, representing clients in numerous corporate transactions and executing patent strategy to advance corporate goals. Ms. Tahl received a J.D. from Boston College Law School and a B.S. in biology from the University of California, San Diego. She is admitted to the state bars of California and New York, and is registered to practice as a patent attorney before the U.S. Patent and Trademark Office.
Bahram (Bob) Valamehr is the Vice President of Cancer Immunotherapy at Fate Therapeutics, overseeing the company’s immuno-oncology and pluripotent stem cell programs, including efforts to develop novel pluripotent cell strategies to create “off-the-shelf” cell-based cancer immunotherapeutics. Previously, Dr. Valamehr has played key scientific roles at Amgen, the Center for Cell Control (a NIH Nanomedicine Development Center) and the Broad Stem Cell Research Center developing novel methods to control pluripotency, to modulate stem cell fate including hematopoiesis and to better understand cellular signaling pathways associated with cancer. He has co-authored numerous studies and patents related to stem cell biology, oncology and materials science. Dr. Valamehr received his Ph.D. from the Department of Molecular and Medical Pharmacology at UCLA, his M.B.A. from Pepperdine University and his B.S. from the Department of Chemistry and Biochemistry at UCLA.
Mr. Beitel is Senior Vice President, Corporate Development, at Fate Therapeutics and is responsible for developing and implementing strategic growth initiatives including expanding the company’s induced pluripotent stem cell (iPSC)-derived cell therapy pipeline through corporate partnerships. Mr. Beitel has more than 20 years of leadership experience in corporate development, strategy, sales and marketing, project management and finance with experience across the spectrum of life science companies. Mr. Beitel was previously Vice President of Corporate Development and Operations at Avanir Pharmaceuticals, where he facilitated the company’s growth into a multi-product organization and the subsequent acquisition of Avanir by Otsuka. Prior to Avanir, Mr. Beitel held various business development, sales and marketing, strategy and finance roles with increasing responsibility at Amgen, La Jolla Pharmaceutical Company and Zacharon Pharmaceuticals. Mr. Beitel holds a Master in Business Administration from Harvard Business School and a Bachelor of Science in Engineering from the University of Kansas.